Products for Research Use Only

Tenovin-6

CAT: 0804-HY-15510-01Size: 2 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15510-01Size:2 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tenovin-6, an analog of Tenovin-1 , is an activator of p53 transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC50s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 also inhibits dihydroorotate dehydrogenase (DHODH)[2].
CAS Number
1011557-82-6
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Dihydroorotate Dehydrogenase; MDM-2/p53; Sirtuin
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Tenovin-6.html
Purity
98.00
Solubility
DMSO : ≥ 31 mg/mL
Smiles
O=C(NC(NC1=CC=C(NC(CCCCN(C)C)=O)C=C1)=S)C2=CC=C(C(C)(C)C)C=C2
Molecular Formula
C25H34N4O2S
Molecular Weight
454.63
Precautions
H302, H315, H319, H335
References & Citations
[1]Lain S, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008 May;13 (5) :454-63.|[2]Yuan H, et al. Tenovin-6 impairs autophagy by inhibiting autophagic flux. Cell Death Dis. 2017 Feb 9;8 (2) :e2608.|[3]Yuan H, et al. Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy. Oncotarget. 2017 Feb 28;8 (9) :14912-14924.|[4]Dai W, et al. Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. Sci Rep. 2016 Mar 4;6:22622.|[5]Ladds MJGW, et al. Exploitation of DHODH and p53 activation as therapeutic targets - a case study in polypharmacology [published online ahead of print, 2020 Sep 8]. J Biol Chem. 2020; jbc.RA119.012056.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
SIRT1; SIRT2; SIRT3